- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11. | SAB Biotherapeutics GAAP EPS of -$1.12 | 1 | Seeking Alpha | ||
| 06.11. | SAB Biotherapeutics, Inc.: SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update | 72 | GlobeNewswire (Europe) | Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year. MIAMI, Nov.... ► Artikel lesen | |
| 06.11. | SAB Biotherapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.09. | SAB Biotherapeutics, Inc.: SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference | 1 | GlobeNewswire (USA) | ||
| 12.09. | Oppenheimer keeps Outperform rating on SAB Biotherapeutics shares | 1 | Investing.com | ||
| 09.09. | SAB Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.09. | SAB Biotherapeutics, Inc.: SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 12.08. | SAB Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| SAB BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.08. | SAB Biotherapeutics GAAP EPS of -$0.79 | 1 | Seeking Alpha | ||
| 08.08. | SAB Biotherapeutics, Inc.: SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates | 158 | GlobeNewswire (Europe) | FDA provided clearance to SAB's IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS)... ► Artikel lesen | |
| 08.08. | SAB Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 05.08. | SAB Biotherapeutics, Inc.: SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes | 486 | GlobeNewswire (Europe) | MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing... ► Artikel lesen | |
| 31.07. | SAB Biotherapeutics names Lucy To as CFO | 1 | Seeking Alpha | ||
| 31.07. | SAB Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.07. | SAB Biotherapeutics, Inc.: SAB BIO Appoints Lucy To as Chief Financial Officer | 123 | GlobeNewswire (Europe) | MIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is... ► Artikel lesen | |
| 20.06. | SAB Biotherapeutics, Inc.: SAb Biotherapeutics Rebrands as SAB BIO | 142 | GlobeNewswire (Europe) | New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 30.05. | SAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Departure of Chief Financial Officer | 199 | GlobeNewswire (Europe) | MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human... ► Artikel lesen | |
| 21.05. | SAB Biotherapeutics, Inc.: FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics | 239 | GlobeNewswire (Europe) | MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the "Company" or "SAB"), today announced that the U.S. Food and Drug Administration (FDA) has provided clearance for the... ► Artikel lesen | |
| 20.05. | SAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates | 251 | GlobeNewswire (Europe) | MIAMI, May 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing... ► Artikel lesen | |
| 16.04. | SAB Biotherapeutics, Inc.: SAB Biotherapeutics Provides SAB-142 Trial Update | 131 | GlobeNewswire (Europe) | MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform... ► Artikel lesen |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 108,50 | 0,00 % | Biontech und Pfizer zahlen für Vergleich in USA | MAINZ (dpa-AFX) - Der Impfstoffhersteller Biontech hat in den USA im Streit um Lizenzgebühren millionenschwere Vergleiche geschlossen. Insgesamt umgerechnet 1,2 Milliarden Euro werden das Unternehmen... ► Artikel lesen | |
| CUREVAC | 2,952 | -0,27 % | CureVac SCHOCKIERT Anleger: Steht die Aktie jetzt vor einem Kursdesaster? | ||
| AMGEN | 250,05 | -0,20 % | Looking At Amgen's Recent Unusual Options Activity | ||
| EPIGENOMICS | 1,120 | +0,90 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| NOVAVAX | 7,835 | -0,48 % | NOVAVAX INC - 8-K, Current Report | ||
| BIOGEN | 144,90 | +0,59 % | Biogen Inc. (BIIB): Among the Cheap Healthcare Stocks to Buy Heading Into 2025 | ||
| MAINZ BIOMED | 5,695 | 0,00 % | Mainz Biomed Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| INTELLIA THERAPEUTICS | 11,555 | +1,67 % | Intellia Therapeutics, Inc. (NTLA): Is This Gene Therapy Stock a Good Buy Right Now? | ||
| VIKING THERAPEUTICS | 38,840 | -0,84 % | Unpacking the Latest Options Trading Trends in Viking Therapeutics | ||
| BIOCRYST PHARMACEUTICALS | 7,294 | -0,33 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,426 | +0,24 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,236 | +0,16 % | Cardiol Therapeutics Sees Insider Buying From Leadership Team And Board Members | ||
| EXELIXIS | 33,040 | +1,23 % | Brookline Capital setzt 40 US-Dollar Kursziel für Exelixis-Aktie mit Kaufempfehlung | ||
| SAREPTA THERAPEUTICS | 115,55 | +0,17 % | Sarepta Therapeutics, Inc. (SRPT): Is This Gene Therapy Stock a Good Buy Right Now? | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,752 | -0,77 % | Pacific Biosciences Of California, Inc. Q3 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Pacific Biosciences of California, Inc. (PACB) reported Loss for third quarter that decreased from the same period last year and beat the Street estimates.The company's... ► Artikel lesen |
SAB BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 4,150 Euro und damit +0,24 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SAB BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.
